N-carbobenzoxy-L-glutamic acid α-N-succinimidyl γ-benzyl diester | 67413-34-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-carbobenzoxy-L-glutamic acid α-N-succinimidyl γ-benzyl diester
• 英文别名: O^γ-benzyl-N^α-benzyloxycarbonylglutamic acid succinimidyl ester；Z-Glu(Bn)-OSu；Z-Glu(obzl)-osu；5-O-benzyl 1-O-(2,5-dioxopyrrolidin-1-yl) (2S)-2-(phenylmethoxycarbonylamino)pentanedioate
• CAS: 67413-34-7
• 化学式: C₂₄H₂₄N₂O₈
• 分子量: 468.463
• InChiKey: FSHGVTPZOIGKTM-IBGZPJMESA-N

物化性质

• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  34
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-carbobenzoxy-L-glutamic acid α-N-succinimidyl γ-benzyl diester 在 碳酸氢钠 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES

  摘要：

  该发明提供了一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一种络合剂。聚合物与络合剂在宿主-客体或客体-宿主相互作用中相互作用，形成包含复合物。该发明的治疗组合物可用于传递治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。该发明还涉及一种制备组合物的方法。该方法将治疗剂、具有宿主或客体功能的聚合物以及具有客体或宿主功能的络合剂结合在一起，形成治疗组合物。络合剂与聚合物形成包含复合物。该发明还涉及一种传递治疗剂的方法。根据该方法，在确实需要治疗的已知需要治疗的哺乳动物（例如人或动物）体内给予该发明的治疗组合物的治疗有效量。还披露了具有以下结构的化合物：

  公开号：

  US20170049903A1
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 5-苄基-N-Cbz-L-谷氨酸酯 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-carbobenzoxy-L-glutamic acid α-N-succinimidyl γ-benzyl diester
  参考文献：
  名称：

  Noda, Kosaku; Igata, Keiko; Horikawa, Yoshiko, Agricultural and Biological Chemistry, 1980, vol. 44, # 10, p. 2419 - 2424

  摘要：

  DOI：

文献信息

• Study on the Structure Activity Relationships of NPTX-594, a Spider Toxin Belonging to the Type-B Acylpolyamine Structure
  作者：Tateaki Wakamiya、Tomohiko Kinoshita、Yoshihide Hattori、Yoshihiro Yamaguchi、Hideo Naoki、Gerardo Corzo、Terumi Nakajima

  DOI：10.1246/bcsj.77.331

  日期：2004.2

  In order to elucidate the structure activity relationships of the spider toxin termed NPTX-594, eleven toxin analogs were designed and synthesized, and their paralytic activities against cricket we...

  为了阐明被称为 NPTX-594 的蜘蛛毒素的构效关系，设计并合成了 11 种毒素类似物，以及它们对蟋蟀的麻痹活性...
• Compositions containing inclusion complexes
  申请人：Pun Hwang Suzie

  公开号：US20060182795A1

  公开（公告）日：2006-08-17

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of prepariing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

  本发明提供了一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一种络合剂。聚合物与络合剂通过主客或客主相互作用形成包含复合物。本发明的治疗组合物可用于传递治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。本发明还涉及一种制备组合物的方法。该方法将治疗剂，具有主或客功能的聚合物以及具有客或主功能的络合剂结合在一起形成治疗组合物。络合剂与聚合物形成包含复合物。本发明还涉及一种传递治疗剂的方法。根据该方法，在需要治疗的哺乳动物（例如人或动物）中，将本发明的治疗组合物的治疗有效量给予。还公开了具有以下结构式的化合物：
• Complexing agents for compositions containing inclusion complexes
  申请人：Pun Hwang Suzie

  公开号：US20070128167A1

  公开（公告）日：2007-06-07

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

  本发明提供了一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一个络合剂。聚合物与络合剂通过主-客体或客-主体相互作用形成包含复合物。本发明的治疗组合物可用于输送治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于将功能引入治疗组合物中。本发明还涉及一种制备组合物的方法。该方法将治疗剂、具有主或客体功能的聚合物和具有客体或主体功能的络合剂结合以形成治疗组合物。络合剂与聚合物形成包含复合物。本发明还涉及一种输送治疗剂的方法。根据该方法，将本发明的治疗组合物的治疗有效量注入需要治疗的哺乳动物（例如人或动物）中。还公开了具有以下式的化合物：
• COMPOSITIONS CONTAINING INCLUSION COMPLEXES
  申请人：Pun Suzie Hwang

  公开号：US20110182864A1

  公开（公告）日：2011-07-28

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

  本发明提供一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一个络合剂。聚合物与络合剂通过主客或客主相互作用形成包含物复合物。本发明的治疗组合物可用于输送治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。本发明还涉及一种制备组合物的方法。该方法将治疗剂、具有主客或客主功能的聚合物和具有客或主功能的络合剂结合起来形成治疗组合物。络合剂与聚合物形成包含物复合物。本发明还涉及一种输送治疗剂的方法。根据该方法，在需要治疗的哺乳动物（例如人或动物）中，向其注射本发明的治疗组合物的治疗有效量。还公开了具有以下公式的化合物：
• Direct PCR amplification of various modified DNAs having amino acids: Convenient preparation of DNA libraries with high-potential activities for in vitro selection
  作者：Masayasu Kuwahara、Kazuo Hanawa、Kazuomi Ohsawa、Rina Kitagata、Hiroaki Ozaki、Hiroaki Sawai

  DOI：10.1016/j.bmc.2005.11.030

  日期：2006.4

  We synthesized modified 2'-deoxyuridine triphosphates bearing amino acids at the C5 position and investigated their substrate properties for KOD Dash DNA polymerase during polymerase chain reaction (PCR). PCR using C5-modified dUTP having an amino acyl group (arginyl, histidyl, lysyl, phenylalanyl, tryptophanyl, leucyl, prolyl, glutaminyl, seryl, O-benzyl seryl or threonyl group) gave the corresponding full-length PCR products in good yield. Although dUTP analogues bearing aspartyl, glutamyl or cysteinyl were found to be poor substrates for PCR catalyzed by KOD Dash DNA polymerase, optimization of the reaction conditions resulted in substantial generation of full-length product. In the case of reaction using dUTP analogue having a cysteinyl group, addition of a reducing agent improved the reaction yield. Thus, PCRs using KOD Dash DNA polymerase together with amino acyl dUTP provide convenient and efficient preparation of various modified DNA libraries with potential protein-like activities. (c) 2005 Elsevier Ltd. All rights reserved.